Effects of Dexmedetomidine on Respiratory Function and Inflammatory Responses in Patient With Sepsis Undergoing Cleaning Focus of Infection

General Hospital of Ningxia Medical University

Status: Unknown

Conditions: Organ Protection

Treatments: Other: normal saline; Drug: dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT02842437

XM2015071

Details and patient eligibility

About

The purpose of this study is to assess the efficacy of dexmedetomidine on lung protection in patient with sepsis undergoing cleaning focus of infection.

Full description

Sepsis is one of the most common, life-threatening medical conditions and is frequently complicated by organ failures, especially lung injury. It is well accepted that inflammatory reaction is the major cause of lung injury. Dexmedetomidine (Dex) is a novel α2-adrenoceptor agonist that is primarily used in surgical anesthesia and conscious-sedation. Recently, animal studies have shown that Dex plays an anti-inflammatory role, while it is not known whether Dex possesses any lung protective functions in patients with sepsis. Therefore, the aim of this study is to investigate the efficacy of Dex on lung protection in patient with sepsis undergoing cleaning focus of infection.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patients with sepsis requiring abdominal cleaning focus of infection
• older than 18 years
• American Society of Anesthesiologists (ASA) physical status II-IV.

Exclusion criteria

• Bradycardia
• Atrioventricular block
• Allergic to the drugs
• A history of respiratory disease
• Pregnancy or breast-feeding women

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups, including a placebo group

Dexmedetomidine

Experimental group

Description:

25 patients receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery

Treatment:

Drug: dexmedetomidine

Placebo

Placebo Comparator group

Description:

25 patients receive matching placebo （normal saline）

Treatment:

Other: normal saline